19:01 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Oncology play iTeos raises $75M, outlines clinical plans

iTeos Therapeutics S.A. (Gosselies, Belgium) raised $75 million on June 19 in a series B round led by MPM Capital. Also participating in the round were HBM Partners, 6 Dimensions Capital, Curative Ventures and SFPI as...
19:04 , Jun 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus Cell culture studies suggest inhibiting adenosine kinase, DCK or SLC29A1 could help treat Staphylococcus aureus infection. Screening of a CRISPR single-guide RNA (sgRNA) library in a human lung lymphoblast cell line expressing CRISPR-associated protein...
01:47 , Jun 20, 2018 |  BC Extra  |  Financial News

Oncology play iTeos raises $75M, outlines clinical plans

iTeos Therapeutics S.A. (Gosselies, Belgium) raised $75 million in a series B round led by MPM Capital. Also participating in the round were HBM Partners, 6 Dimensions Capital, Curative Ventures and SFPI as well as...
01:38 , Jun 20, 2018 |  BioCentury  |  Finance

Iterating iTeos

With a new office in the U.S. and $75 million in fresh series B funding to support clinical development of at least two candidates, Belgian cancer company iTeos Therapeutics S.A. is considering a U.S. IPO...
21:50 , Jun 14, 2018 |  BC Innovations  |  Emerging Company Profile

Beaming about base changes

Beam Therapeutics launched with a CRISPR-guided base editor platform that could introduce more precise point mutations than other gene editing technologies without the risk of off-target cuts. Founded by CRISPR veterans David Liu of Harvard University,...
18:26 , Jun 13, 2018 |  BC Innovations  |  Distillery Techniques

Other

TECHNOLOGY: Computational models A method for designing small molecules that bind two protein targets could be used to generate dual inhibitors. The method utilizes in silico docking of a library of drug-like compounds and compound fragments...
05:50 , Jun 2, 2018 |  BioCentury  |  Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
16:44 , May 24, 2018 |  BC Innovations  |  Translation in Brief

Channel for T cell invasion

University of Cincinnati researchers have found that increasing potassium flux through the KCa3.1 channel could boost CD8+ T cell migration into the tumor microenvironment, raising the prospect that this could present a new mechanism to...
21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of investors...
18:06 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Mouse studies suggest nanoparticles loaded with an ADORA2A antagonist and conjugated to CAR T cells could help treat ovarian cancer. The conjugate consists of cross-linked multilamellar liposomal nanoparticles loaded with a tool compound...